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Purpose. To identify the magnitude and sources of variability of a generic, aseptic manufacturing process
for experimental anticancer agents employed at our facility, and to estimate the effects on product
quality.
Materials and Methods. In-process and quality control data of all products manufactured according to
this generic process (composed of weighing, dissolution, filtration, filling, semi-stoppering and
lyophilization) over a 3-year period were retrospectively analyzed using mixed-effects analysis.
Results. Variability in the filling process was shown to be marginal and of minor importance for product
quality in terms of content and content uniformity. An overall content of 101% was found with batch-to-
batch and vial-to-vial variability up to 4.21% and 2.57%, respectively. Estimation of the overall batch
failure revealed that structural bias in content and a high batch-to-batch variability in content were the
most prominent factors determining batch failure. Furthermore, content and not content uniformity was
shown to be most important parameter influencing batch failure. Calculated Process Capability Indices
(CpKs) calculated for each product showed that the process is capable of manufacturing products which
will routinely comply with the specification of 90Y110% for content. However, the CpK values decreased
dramatically using the specification of 95Y105% as required for approved drug products.
Conclusion. These results indicate that at the early stage of product development less tight specification
limits must be applied to prevent unnecessary batch rejection of investigational agents.
KEY WORDS: investigational drugs; manufacture; mixed effects analysis; validation.
INTRODUCTION
The first steps in clinical development of experimental
anticancer agents are phase I and II trials. Product quality,
evidently, is very significant at this stage of development as
it may, apart from patient safety, affect the outcomes of
clinical trials which will determine whether or not the
product will be selected for further development (1).
Therefore, guidelines have been established with respect to
Good Manufacturing Practice (GMP) of investigational
agents (1Y4). Product quality starts off with drug synthesis,
followed by scientific sound formulation-, compatibility- and
stability studies. This also involves the development and
validation of a set of analytical techniques and methods to
enable characterization and quality control of both the active
pharmaceutical ingredient (API) and the final pharmaceuti-
cal product. Consistent manufacturing of the pharmaceutical
product of the required quality should be possible then and
proven by validation studies (5).
In our institute we have a long experience in the
pharmaceutical development and manufacture of experi-
mental anticancer agents for phase I and II clinical trials
(6Y15).
Anticancer drug formulations for experimental use are
generally intended for intravenous administration to obtain
absolute bio-availability, to circumvent possible disturbance
of or degradation in the gastrointestinal tract and to be able
to adjust or to stop administration of the drug immediately in
case of acute toxicity. Consequently, the development of a
pharmaceutical formulation of a novel anticancer agent is
focussed on issues associated with the design of sterile and
stable injectable products.
General characteristics in this early phase of develop-
ment are: often limited availability of API, precluding
elaborate validation studies; small scale (both in number
of units per batch as well as in number of batches);
flexibility (due to relatively many changes in strength and/
or composition of batches); aseptical manufacturing process
as the instability of the APIs often does not allow heat
sterilization.
For the manufacture of sterile anticancer agents in the
early phase of development, we established a small manu-
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production process capable of handling intravenous investi-
gational anticancer drugs with the characteristics inherent to
this phase. The generic production process is composed of six
steps: weighing, dissolution, filtration, filling, semi-stopper-
ing, and lyophilization.
The aim of this study was to identify the magnitude and
sources of variability of the production process and to
estimate the effects on product quality. Therefore, we
performed a retrospective validation of this generic manu-
facturing process using mixed effects analysis. Based on this
analysis, we evaluated the specifications for investigational
products.
MATERIALS AND METHODS
Manufacturing Process
A flow chart of the generic production process,
including the in-process controls which are performed at
the different processing steps, is depicted in Fig. 1. All
manufacturing steps are performed in a class 100 (B) clean
room facility. Manipulations with open product (filtration,
filling, semi-stoppering, lyophilization) are performed in a
class 100 (A) environment. The clean room facility is
regularly validated with respect to viable (settle plates, air
sampling, contact plates) and non-viable particles, both in the
Bat rest state’’ and at operating state situation. Also, the
aseptic manufacturing process and personnel is regularly
validated by media fills by simulating the complete manufac-
turing process. Suitability of sterilizing filters for the manu-
facture of a specific product is evaluated. This all according
to current guidelines (16,17). The facility holds a man-
ufacturer_s licence for the manufacture of experimental
anticancer agents since 1999.
Data Collection
Data (i.e., batch characteristics and quality control data)
were collected of all batches manufactured between January
2003 and November 2005. The following batch characteristics
were used as input variables: product, batch size, dissolution
vehicle, and theoretical filling volume. Table I gives an
overview of the batch characteristics and their ranges. Output
variables were: filling weight, content, and content uniformity.
Data Analysis
For all batches, two types of observations were available:
1. In-process controls during the filling process (=filling
weight)
2. Overall content (n=13) of the vials calculated from both
the content uniformity (n=10) and content (n=3) data
Both parameters were expressed as percentage of the
theoretical values in order to facilitate comparison of the
different batches and products.
Retrospective Data Analysis: Basic Model
Three distinct types of variability were assumed to exist:
1. Structural bias: The occurrence of a structural deviation
from the theoretical content may be due to e.g., the
production process, characteristics of the API (e.g.,
absorbance to materials used during manufacture) or
filling of very low volumes.
2. Batch-to-batch variation (i.e., variation between different
batches of one product)
3. Vial-to-vial variation (i.e., variation within one batch)
The basic model applied for data obtained from the
filling process was:
Fij ¼  ij þ  fill;j þ "fill;ij
in which Fij is the measured filling weight in vial i of batch j,
qfill is the typical value of the filling weight (if no structural
bias is present qfill=100%),  fill,j is a random effect describing
batch-to-batch variability with mean 0 and a standard
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Fig. 1. Schematic representation of the generic production process.
Table I. Batch Characteristics of all Batches Manufactured from
2003 to 2005 Used for Validation
Batch Characteristic Range
No. of products 7
No. of batches 97
Batch size 75Y800 vials
Dissolution vehicle DMSO, WfI, TBA/WfI
a
API concentration
b 0.5Y150 mg/ml
Filling volume 1Y40 ml
aDMSO dimethyl sulfoxide, WfI water for injection, TBA/WfI 40%
v/v TBA in WfI.
bConcentration of API in the formulation solution.
606 Schoot, Nuijen, Huitema, and Beijnendeviation of wfill, and efill,ij is the random effect describing
vial-to-vial variability with mean 0 and standard deviation
sfill.
The predicted filling weight for an unknown vial in batch
j equals Fj ¼  fill þ  fill;j
Similarly, the content data were modelled as:
Cij ¼ WT   Fj    cont þ  cont;j þ "cont;ij
in which Cij is the measured content of vial i of batch j,W Ti s
the weighted amount of API (expressed as percentage of
theoretical), qcont is the typical value of content,  cont,j is a
random effect describing batch-to-batch variability with
mean 0 and standard deviation wcont and econt,ij is the random
effect describing vial-to-vial variability with mean 0 and
standard deviation scont. Because weighing is performed on a
calibrated balance, it was assumed that bias and precision of
the weighing could be neglected compared to the other
sources of variability.
Both models were simultaneously applied to the data
containing both types of observations (in-process controls
during the filling process, and Overall content of the vials
calculated from the content uniformity and content). Non-
linear mixed effects modelling (NONMEM, version V,
double precision, level 1.1, Globomax, Ellicott City, MD,
USA) was used for the data analysis. NONMEM applies a
maximum likelihood criterion to simultaneously estimate
fixed effects (i.e., the typical values of content and the filling
process) and random effects (i.e., the different variability
terms). The first-order conditional estimation method with
interaction between different types of variability (INTER-
ACTION option of NONMEM) was used throughout. The
following fixed effects were estimated for the basic model:
qfill and qcont. The following random effects were estimated:
wfill, sfill, wcont and scont. Precision of parameter estimates was
obtained with the COVARIANCE option of NONMEM.
Retrospective Data Analysis:
Influence Of Production Parameters
For all batches the following co-variates were recorded:
product (PROD), batch size (SIZE), filling volume (FILL)
and, vehicle (VEH). The influence of these co-variates was
tested on the different terms in the model. For instance, a
product may have a systematic bias, an increased batch-to-
batch variability or an increased vial-to-vial variability. The
influence of these co-variates on the random effects was
tested by introduction of different random effects terms for
data with and without the co-variate (i.e., one product
compared to the other products). The influence on the fixed
effects was tested by introduction of a separate fixed effect
describing the systematic bias for that co-variate. Significance
was tested using the likelihood ratio test. The difference in
objective function (minus twice the log likelihood of the
data) between two nested models (i.e., models with and
without a co-variate influence) has a chi-square distribution
with one degree of freedom. Therefore, a difference of 3.84
points corresponds with a p value of 0.05.
Possible co-variates were introduced separately on the
different terms of the basic model. Subsequently, all possible
significant co-variates were introduced in an intermediate
model. Stepwise backward elimination was used to retain
only the significant co-variates in the final model.
Furthermore, the Process Capability Index (CpK) was
calculated. This parameter is often used to measure the
reproducibility as a function of the specification limits (18).
CpK values were calculated for each product assuming a
content equal to the average content for this product
(optimal situation resulting in an Bideal’’ batch) and for each
product assuming a content equal to the average content T1
R.S.E. batch-to-batch variability, using Eqs. 1 and 2, which-
ever gives the lowest number.
CpK ¼
upper limit of specification   mean
3   standard deviation
ð1Þ
or
CpK ¼
mean   lower limit of specification
3   standard deviation
ð2Þ
For the calculation of the CpK values the specification
limits for content of 90Y110% and 95Y105% were used.
Simulation Studies
Based on the results of the retrospective data analysis,
several simulations were performed in order to characterize
the influence of different production parameters on batch
failure (both content and content uniformity). For content
uniformity the specifications according to the European
Pharmacopoeia (19) were used, for content an average of
90Y110% was used as specification. Several scenarios were
investigated in which different sets of production parameters
were defined and the influence of these parameters on batch
failure was investigated. For each scenario, 1,000 batches
were simulated and subsequently the batch failure based on
content, content uniformity and overall batch failure was
recorded. Simulations were performed using the SIMULA-
Table II. Variables Which May Influence Product Quality
Product Quality Item Process Variable
Appearance Freeze-drying process
Reconstitution
characteristics
Freeze-drying process
Content Filling weight (IPC)
Content uniformity Filling weight uniformity (IPC)
Purity Purity API
Processing time
pH after reconstitution Concentration/characteristics
of API and/or excipients
Residual moisture/solvent
content
Freeze-drying process
Sterility API/excipients/bioburden of
formulation solution (IPC)
Filter integrity (IPC)
Clean room/personnel performance
Bacterial endotoxins Contamination of API and/or
excipients
Clean room/personnel performance
IPC in-process control.
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the retrospective data analysis.
RESULTS AND DISCUSSION
Manufacturing Process
Table II gives a list of standard quality control test items
for sterile, lyophilized products for parenteral use and the
variables which may affect these. From these, the items and
in-process controls were selected which are critical for
product quality and are indicative for the general perfor-
mance of the production process in relation to batch
characteristics (product, batch size, dissolution vehicle,
theoretical filling volume) were selected. The decision tree
used to designate a variable as critical is given in Fig. 2. The
test items Appearance, Reconstitution characteristics, and
Residual moisture or solvent content are all output variables
which are inherent to the selected freeze-drying process and
are product-specific. Also, they influence more critical
product quality items like content and purity only indirectly
and are for this reason considered non-critical. Therefore,
these items were not included in the assessment. For the
same reason, pH after reconstitution was not used. Purity was
not used because for all products analyzed the stability was
studied well during formulation development and the com-
pounds of interest were shown to be stable during processing
time. Of all batches analyzed, no deviations in the manufac-
turing process occurred which may have affected purity or
content. The test items content and content uniformity,
however, were selected for the assessment because they are
critical items for product quality. As shown from Table II,
both content and content uniformity are directly influenced
by filling weight and filling weight uniformity. Therefore, the
in-process control filling weight was used in the analysis as
well. Controls for producing an investigational new drug are
primarily aimed at patient safety (4). Because it concerns the
manufacture of parenteral drugs, sterility and pyrogenicity
immediately affect product safety and are therefore critical
items. The sterility and bacterial endotoxins content of all
batches used for the assessment were according to the
specifications. However, the tests performed to determine
sterility and pyrogenicity are only performed on a selected
number of vials and therefore, a negative result does not
completely guarantee that all vials are sterile and free of
endotoxins. This emphasizes that minimizing bioburden
during manufacture and validation of production personnel,
clean room facilities and production process is of utmost
importance. No critical deviations with respect to these items
occurred during the period of analysis.
Data Analysis
Retrospective Data Analysis: Basic Model
In total, data of 97 batches of seven products were used
for the retrospective risk assessment.
Variation in content or content uniformity found by
quality control analysis is the result of an addition of errors in
weighing, filling, and analytical variation. Due to the
performance of extensive formulation and stability studies,
it can be assumed that no degradation or loss during
dissolution, filtration and freeze-drying occurs during the
production process. The overall accuracy of the filling
process was 99.6%, with a batch-to-batch and vial-to-vial
variability of 0.796 and 0.988%, respectively (Table III).
During manufacture of each batch, the pump was calibrated
using the freshly prepared formulation solution which might
Affects safety?
Affects product 
quality?
Operation 
near proven 
acceptable 
range?*
Other justification?
CRITICAL
NOT
CRITICAL Yes
Yes
No
No
Yes
No
No
Yes
Yes
Fig. 2. Decision tree for determination of product quality. Asterisk:
generally unknown at early stage of drug development.
Table III. Results of the Retrospective Data Analysis: Basic Model
Typical Value (%) (%R.S.E) Batch-to-Batch Variability (%) (%R.S.E) Vial-to-Vial Variability (%) (%R.S.E)
Filling process 99.6 (0.089) 0.796 (20) 0.988 (23)
Content 101 (0.40) 3.89 (19) 1.96 (16)
%R.S.E. Percent relative standard error of estimate
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pared to the vial-to-vial variability, although this difference is
small.
For content, an overall accuracy of 101% was found,
while batch-to-batch variability and vial-to-vial variability
were approximately 4 and 2%, respectively. This indicates
that variability in the filling process is only marginal
compared to the variability in content and therefore of minor
relevance for the overall product quality.
Retrospective Data Analysis:
Influence of Production Parameters
With this analysis, it was tested whether different
production parameters had impact on the performance of
the production process. This analysis, however, was ham-
pered by the fact that several co-variates showed some
degree of co-linearity. For instance, the dissolution vehicle
dimethyl sulfoxide (DMSO) was only used as vehicle in a
single product. Therefore, it was impossible to differentiate
between the influence of DMSO as vehicle or other specific
properties of this product (e.g., quality control methods). In
these cases, it was chosen to use the product first as co-
variate, except for co-variates related to the filling process
where filling volume and vehicle were used preferentially.
Table IV shows the results of this analysis. As can be seen,
two products (3 and 5) had a systematic lower filling weight
and one product (product 7) showed a lower batch-to-batch
variability in the filling process than the other products. In
product 3 the excipient 2-hydroxypropyl-"-cyclodextrin was
used, resulting in a slight increase in viscosity of the formu-
lation solution, probably resulting in a decrease in filling
volume. For the vial-to-vial variability almost a three-fold
increase (from 0.735 to 1.99%) was seen when a fill volume
of 1 ml was used compared to higher filling volumes of
2Y40 ml. Furthermore, the use of DMSO as vehicle increased
the vial-to-vial variability with 53%, while the use of a
mixture of water and tert-butyl alcohol (TBA) reduced this
variability with 33.9%.
The typical value of the overall content was exact
100%, indicating that no general structural bias was
present. However, products 2 and 6 had a systematic and
significant bias of Y5.04 and +7.14%, respectively. This bias
is not due to variation in filling weight, because no
deviation in the typical value of the overall filling of these
products was seen (Table IV). No specific product character-
istics could be related to the structural bias of these products.
Further investigation of the cause of the structural bias is
required.
The batch-to-batch variability of the overall content was
4.21% while product 3 and 7 had a significant lower vari-
ability of less than 2%. Vial-to-vial variability was estimated
for all products separately in order to account for differences
in quality control methods. Vial-to-vial variability in content
ranged from 1.51 to 2.57%. The highest vial-to-vial variability
was found for product 4. Remarkable is the low vial-to-vial
Table IV. Results of the Retrospective Data Analysis: Influence of Production Parameters
Typical Value
(%) (%R.S.E)
Batch-to-Batch Variability
(%) (%R.S.E)
Vial-to-Vial Variability
(%) (%R.S.E)
Overall filling process 99.8 (0.063) 0.857 (19) 0.735 (20)
Product 3 j0.552
a (37)
Product 5 j0.892
a (40)
Product 7 0.251
b (59)
FILL=1 ml 1.99
b (49)
VEH=DMSO +53%
a (87)
VEH=TBA/WfI j33.9%
a (75)
Overall content 100 (0.28) 4.21 (22)
Product 1 1.65
b (11)
Product 2 j5.04
a (32) 2.04
b (64)
Product 3 1.95
b (28) 1.51
b (21)
Product 4 2.57
b (33)
Product 5 1.52
b (16)
Product 6 +7.14
a (28) 2.06
b (21)
Product 7 1.53
b (30) 2.12
b (30)
FILL filling volume, VEH dissolution vehicle, DMSO dimethyl sulfoxide, TBA/WfI 40% v/v tert-butyl alcohol in water for injection, %R.S.E.
% relative standard error of estimate.
aRelative difference compared to typical value.
bAbsolute value.
Table V. Calculated CpK Values for Content
Product
Limit 90Y110% Limit 95Y105%
Mean
a MeanT1 bbv
b Mean
a MeanT1 bbv
b
1 2.02 1.17 1.01 0.16
2 0.81 0.12 j0.01 j0.69
3 2.21 1.78 1.10 0.67
4 1.30 1.04 0.65 0.40
5 2.19 1.77 1.10 0.67
6 0.46 0.15 j0.35 j0.66
7 1.57 1.33 0.79 0.55
aCpK value calculated for the most ideal batch with a batch-to-batch
variability of 0.
bCpK value calculated for a batch with a deviation of 1 batch-to-
batch variability (bbv).
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because this product is analyzed using a derivatization step,
which may inherently increase variability. Apparently, the
derivatization process is robust.
Furthermore, the Process Capability Index (CpK) was
calculated for each product. There are generally accepted
rules to relate the CpK value to the robustness of the
process. A CpK value of less than or equal to 0.8 indicates
that the process is not capable of meeting the specification
limits routinely and therefore, further efforts have to be
made in developing a more robust process. CpK values of
0.9Y1.0 indicate a marginal process, of 1.0Y1.25 are
satisfactory, of 1.25Y1.5 are good, and values higher than
1.5 are excellent. The calculated CpK values of our products
are given in Table V. Within the limits of 90Y110% and a
deviation of one batch-to-batch variability, products 2 and
6 had a CpK value of less than 0.8, indicating that the
process was not able to meet the specifications routinely
for these products. The CpK values of the Bideal’’ batches
of these products, however, were not much better. This is
due to the structural bias found for these products. The
presence of a structural bias can be a pitfall when using
CpK values, because it can result in a low CpK value
while the manufacturing process is acceptable and vice
versa (18). The CpK values were satisfactory for products 1
and 4, good for product 7 and excellent for products 3 and 5.
As expected, using the specification limits of 95Y105%
according to the European guidelines for approved drugs,
the CpK values were lower (20). The CpK values were less
than 0.8 for all products with a deviation of one batch-to-
batch variability. For the Bideal’’ batches, the CpK values of
four of the seven products were still less than 0.8. It should
be noted that the estimates for batch-to-batch variability
were based on a limited number of batches. These values
may therefore be highly dependent on single outlying
batches. Further process optimization may be required
before the products can fulfil the specifications for ap-
proved drug products routinely, especially when no outliers
were found.
Simulation Studies
From the retrospective data analysis, it was established
between which limits the different terms of the model
varied according to the different production parameters.
The ranges for the different terms were used in simulation
studies to assess the influence of the different parameters
on batch failure. The ranges used in the simulation study
are shown in Table VI. The lower limits were defined as the
bestcasescenario,theupperlimitsweredefinedastheworstcase
scenario.
In a first series of simulations, it was investigated to what
extent parameters derived from the filling process influenced
the results. In the best case scenario as well as the worst case
scenario no batches (out of the 1,000 simulated batches) were
out of specifications for content and/or content uniformity.
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Fig. 3. Calculated effect of vial-to-vial and batch-to-batch variability on the risk of batch failure based on the content and content uniformity
in absence of structural bias.
Table VI. Parameter Ranges for Simulation Study
Filling Process (%) Content (%)
Absolute structural bias 0Y10 Y7
Batch-to-batch variability 0.25Y1 1.5Y5
Vial-to-vial variability 0.75Y3 1.5Y2.5
610 Schoot, Nuijen, Huitema, and BeijnenTherefore, it was concluded that the filling process was not a
critical step in the manufacturing process within our current
assessment.
The results of the same series of simulation for content
are shown in Fig. 3. As can be seen, an increased batch-to-
batch variability in content (1.5 to 5%, Table VI) was the
most prominent factor determining batch failure in the
absence of a structural bias. Furthermore, it was observed
that the batch-to-batch variability had more impact on
content than on content uniformity. It should be noted that
overall batch failure was only determined by failure on
content and not on content uniformity.
In a next step, the influence of a structural bias in
content and content uniformity on the chance of batch failure
was tested. This was performed using a best and a worst case
scenario (indicated in Table VI). The results of these
simulations are shown in Figs. 4 and 5. Again, overall batch
failure was only determined by batch failure due to content
being out of specification. In the worst case scenario defined
in our retrospective analysis (for all parameters involved) a
structural bias of 7% in content could be found (Table VI),
resulting in an overall content of 93 or 107%. In this situation
approximately 30 and 15% of the batches are out of
specification for content and content uniformity, respectively
(Fig. 5). Caution should be taken in interpretation of these
results as it is a simulation of the worst case scenario for all
parameters simultaneously, which has not been encountered
in practice thus far. Nonetheless, it indicates that structural
bias has an important influence on batch failure.
Overall it was found that within the limits as found in
our retrospective data analysis, a structural bias in content
and a high batch-to-batch variability in content are the most
prominent factors determining batch failure. A variation in
structural bias from Y5 to +7% was seen. The presence of
such a bias would result in a dramatic increase in batch
failure if the limits 95Y105% for content, according to the
European guidelines for approved drugs, were used (20).
These results indicate that at the early stages of product
development, less tight specification limits must be applied to
prevent unnecessary batch rejection of investigational agents.
It is generally accepted that product specifications will evolve
during development, starting off with relative wide limits
followed by tightening of these specifications in the course of
product development as more information is gained and
manufacture and analysis becomes more qualified (18,21Y24).
It is shown that the 90Y110% specification limits we apply for
content is feasible in this respect.
CONCLUSION
This analysis showed that for our generic manufacturing
process, variability in the filling process was marginal and of
minor importance for product quality in terms of content and
content uniformity although it can be influenced by produc-
tion parameters like dissolution vehicle and filling volume.
An overall content of 101% was found with batch-to-batch
and vial-to-vial variability up to 4.21 and 2.57%, respectively.
Estimation of the overall batch failure revealed that struc-
tural bias in content and a high batch-to-batch variability in
content were the most prominent factors determining batch
failure. Furthermore, content and not content uniformity was
shown to be most important parameter influencing batch
failure. Calculated Process Capability Indices (CpKs) were
calculated for each product, which showed that our manu-
facturing process is capable of manufacturing products which
will routinely comply with the specification of 90Y110% for
content. However, the CpK values decreased dramatically
using the specification of 95Y105% as required for approved
drug products. These results indicate that at the early stages
of product development, less tight specification limits must
be applied to prevent unnecessary batch rejection of inves-
tigational agents. Mixed effect analysis was shown to be a
valuable tool in the assessment of the performance of our
manufacturing procedures, and is implemented as an adju-
vant to the application of GMP at our facility.
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